Watch past educational presentations and see live events in real time
Reference our medication guides for helpful information
The application for the FIT Subcommittee is open. Apply by August 30.
Make a choice that matters
The best care starts with the best information
Encourage your fellows to apply for the FIT Subcommittee by August 30.
The original purpose of the six minute walk was to test exercise tolerance in chronic respiratory disease and heart failure. The test has since been used as a performance-based measure of functional exercise capacity in other populations including healthy older adults, people undergoing knee or hip arthroplasty, fibromyalgia, and scleroderma. It has also been used with children.
The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. The individual is allowed to self-pace and rest as needed as they traverse back and forth along a marked walkway.
The 6MWT was developed in 1963 by Balke to evaluate functional capacity1. Different variations of the timed walk have been tested, and the six minute timed walk was recommended given its reproducibility and ease of administration compared to longer timed tests2. Later studies showed that timed walks under 4 minutes were found to be not as sensitive to evaluate the differences in walked distances3,4.
Number of items in scale: Not applicable.
Subscales: Not applicable.
The 6MWT was developed in frail elderly patients 60-90 years of age referred to a geriatric hospital, and it targets community dwelling frail elders1. However, the test has been used in a variety of chronic disease adult and pediatric populations as well as in healthy adults.
The 6MWT has also been used to detect changes following interventions to improve exercise tolerance for healthy older adults5,6 as well as people with rheumatic conditions such as knee or hip osteoarthritis7 and fibromyalgia8. The 6MWT has been used with a variety of other conditions such as heart failure9,10, chronic obstructive pulmonary disease (COPD)11 and stroke12, 13 It has also been used to predict hospitalization and mortality6,14.
World Health Organization (WHO) International Classification of Functioning, Disability and Health (ICF) Components: changing and maintaining body position (d410-d429) and walking (d450).
This is ideally conducted in an enclosed, quiet hallway by a single administrator. However, it is important to note that there are variations among studies in how the test is conducted which affects performance. These variations include the instructions provided to the participant, the number of turns in the course, the frequency and type of encouragement given, and the number of trials performed. Each of these variations will be outlined briefly.
Time to administer/complete: 15 minutes or less.
Availability/cost: Readily available
Outcomes measured: The primary outcome is the distance covered in meters or converted measure (such as feet) over 6 minutes. To measure functional aerobic capacity or general fitness, this test may be used in conjunction with VO2 testing (often using a portable metabolic system which measures oxygen uptake during exercise).
Interpretation of scores: A lower score (reflecting less distance covered in 6 minutes) indicates worse function.
Method of scoring: Administrator tallies the total distance walked using the pre-marked intervals as a guide.
Time to score: Minimal
Training to score: Minimal
Training to interpret: None required.
Norms available: The six minute walk distance in healthy adults has been reported to range from 400m to 700m23. Age and sex-specific reference standards are available and may be helpful for interpreting 6MWT scores for both healthy adults and those with chronic diseases 47. However, it is difficult to use normative values because of the differing methods used in studies. An improvement of 54m has been shown to be a clinically important difference24 in a study of people with chronic lung disease which is similar to the recommended criteria of meaningful clinical change of 50m based on analyses from a sample of 692 community living older adults and individuals who have survived a stroke25.
Test/retest. Test-retest reliability has been reported as high, with an ICC of 0.90 at baseline, 0.88 at 18 weeks, and 0.91 at 43 weeks in a cohort of patients with heart failure (HF)26. An ICC of 0.80 (95% CI=0.69-0.87) was reported after one year in a group of patients with CHF and associated comorbidities including diabetes and hypertension27. An ICC of 0.73 to 0.98 has been reported in individuals with fibromyalgia following a timeframe of 10 days or four weeks in two independent studies28, 29.
Content. The 6MWT has been found to have content validity for patients with severe heart failure and pacemakers30, 31. Doubts have been raised about the validity of using the six-minute walk test with individuals with systemic sclerosis in particular with using the test as a measure of change in intervention studies.32.
Criterion. Moderate to high relationships have been reported (r=0.56 to r=0.88) between the 6MWT distance and peak VO2 obtained by maximal exercise testing in persons with heart failure33, 34. Accuracy was 80% and sensitivity and specificity >90% compared to maximal oxygen uptake in 51 heart disease patients.48Â In clients with chronic heart failure, Riley et al.35 found that the peak VO2 in the 6MWT was similar to or higher than peak VO2. In certain subpopulations, the 6MWT sub-maximal test demonstrates moderately high associations with those of maximal exercise tests.
Concurrent validity. A negative correlation was found between the 6MWT distance and the New York Heart Association (NYHA) functional class classification (r=-0.60, n=94) indicating as the distance walked decreased, the NYHA classification increased (i.e., a reduced ability to perform physical activity) 36. A positive correlation existed (r=0.624, n=94) between the 6MWT distance and the SF-36 physical function scale indicating as walk distance increased, physical function increased 36. There was a weak negative correlation (r=-0.26, n=768) between the baseline 6MWT distance and the Minnesota Living with Heart Failure Questionnaire that looks at health-related quality of life26.
Redelmeier et al.24 reported a clinically significant mean change of 54 meters (95% CI, 37-71 m) in patients' perception of exercise tolerance in 112 patients with stable, severe COPD. O'Keeffe et al.10 reported a clinically significant mean change of 43 m in 45 elderly patients with heart failure. They noted more responsiveness to change in deterioration than improvement in people with heart failure. Perera et al.25 described a meaningful clinical change of 50m based on analyses from a sample of 692 community living older adults and individuals who have survived a stroke. However, the minimal clinically important difference is slower, 25 meters, for coronary disease patients after acute coronary syndrome.49
Olsson et al.37 performed a systematic review to assess the 6MWT's ability to measure change over time following the use of pharmacological and non-pharmacological interventions. A total of 46 placebo-controlled trials were reviewed. Thirty-nine of the trials involved pharmacological interventions and seven trials included non-pharmacological treatments. Results indicate significant changes in 6MWT distance in four out of seven of the non-pharmacological trials and only nine out of 39 pharmacological trials. O'Keeffe et al.10 assessed the reproducibility and responsiveness in patients with heart failure between a quality of life assessment and the six-minute walk test. In this case, the degree of correlation between the 6MWT distance and the global rating of change in cardiac status was good (r=0.78).Â Olper et al46, reports the standard hallway method has slightly better responsiveness to change (effect size 0.9) than the treadmill 6MWT (effect size 0.6).
The six-minute walk test (6MWT) was first used in the clinical setting to test exercise tolerance in individuals with chronic respiratory disease and respiratory failure. Current literature reports its use as a submaximal exercise test to measure functional exercise capacity (i.e., the ability to engage in physically demanding activities of daily living)22 in individuals with a wide variety of characteristics including healthy older adults and those with chronic heart and lung disease, heart failure, fibromyalgia, peripheral arterial disease and neurological conditions38 as well as with older adults. With respect to the potential limitations in scleroderma, the pervading theme is that the 6MWT's lack of discriminative ability and association with clinical worsening, limit its use as an outcome measure for clinical trials32, 39. While it is a practical and simple test that can be repeated to determine changes associated with the implementation of an intervention designed to improve functional capacity, the multi-system nature of scleroderma and other rheumatic conditions, as well as the common co-morbidities present in an aging population, hinders the ability to 6MWT to document organ or system-specific changes32 associated with interventions. Moderate to strong correlations exist (r=0.56 to r=0.88) between the 6MWT distance and peak VO2 obtained by maximal exercise testing33, 34. Variations in testing methods that allow for a learning effect or motivation through verbal cuing may lead to disparate results. The American Thoracic Society released guidelines for the 6MWT and suggests adherence to standardized methods to minimize variances.
Evidence suggests that variations in psychometric properties exist based on type of diagnosis. The minimally clinical important difference reportedly varies based on diagnosis.
It is suggested that the 6MWT may be useful as a self-administered outcome tool4. Although not thoroughly investigated, the authors indicate that promoting self-awareness and management of physical activity, such as walking, can inform the individual of changes in their health status, which may prompt a change in interventions. Further research is needed in this area.
This review has primarily focused on the use of the 6 minute walk test in adults. There have been some studies of the 6 minute walk as a test of exercise or aerobic capacity in children (either who were considered healthy or those with varying chronic conditions)40-43. Similar to the studies in adults, differences in administration of the 6 minute walk makes results of these studies difficult to synthesize. Age, height, and weight are often factors that affect 6 minute walk times40-43.
Reliability estimates (ICC) in children range from 0.96 - 0.98 and minimal clinically important differences are highly variable and likely depend heavily on the type of chronic condition50. Pearson correlations between 6MWT and VO2max are also highly variable ranging from -0.25 to 0.4650. Among children with juvenile idiopathic arthritis (JIA), the 6 minute walk was associated with submaximal levels of exercise intensity suggesting it is a good measure of functional capacity43.
In another study in which children with JIA were a subgroup, 6 minute walk distance multiplied by body weight was a stronger measure than 6 minute walk distance alone. Recently the 6MWT has been used as an outcome measure in weight loss studies and may be a practical and promising assessment tool for exercise performance in the obese pediatric population 51, 52.
Further work is needed to test the 6 minute walk in children with rheumatologic conditions using standardized protocols.
Reviewed 2015 by the ARP Research Committee